Why PERSONA Matters
The PERSONA trial is at the forefront of preventive medicine, offering high-precision genomic assessment for those looking to understand their personal health risks. By analyzing specific genetic markers linked to breast and ovarian cancer in women aged 20-39, we provide the foundational data needed for personalized screening plans and proactive wellness strategies.

Who can join?

Age Group
Participants must be between 20 and 39 years of age at the time of enrollment.

Birth Record
The trial is open to individuals who were recorded female at birth (AFAB).
If you meet these criteria, you are eligible to proceed with the registry process and assessment.
The Enrollment Process

1. Review Trial Infomation
Start by learning about the PERSONA study goals and how your participation helps advance breast and ovarian cancer research.

2. Provide Consent
Review and sign the Participant Information and Consent Form (PICF) through our secure, HIPAA-compliant digital portal.

3. Genomic Testing
Complete your genomic test using a simple, non-invasive saliva or blood sample provided at a participating GP clinic.

4. Receive Results
Access your personalized cancer risk assessment results securely, handled with the highest standards of genetic data privacy.

Simple & Secure Testing
The PERSONA trial utilizes a simple saliva or blood sample to analyze gene variants associated with breast and ovarian cancer risk. Your genetic data is handled with the highest standards of security and clinical encryption, ensuring your health information remains strictly confidential and protected throughout the study process.
Watch: Understanding PERSONA
Common Questions
How is my privacy protected?
Your genetic data is stored on high-security servers with robust encryption and strict anonymization protocols. We prioritize participant confidentiality at every stage of the PERSONA trial.
When will I receive results?
The genomic analysis process is comprehensive. Participants typically receive their personalized risk assessment findings within 8 to 12 weeks after submitting their saliva or blood sample.
Who is eligible to join?
The trial is currently open to individuals recorded female at birth, aged between 20 and 39 years, who are interested in understanding their genomic risk for breast and ovarian cancer.
What does the test involve?
The test requires a simple saliva or blood sample. This sample is analyzed for specific gene variants. The process is safe, clinical, and handled by trained professionals in certified laboratories.
